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respectively). However, among patients who 
received sunitinib, grade 3 or 4 treatment-related 
adverse events were higher among those in the 
older age group (55% vs. 70%).
Our results support an age-independent bene-
fit–risk profile of nivolumab plus ipilimumab, 
including in elderly patients. Clinical data are 
lacking to assess any distinctive changes in the 
cellular immune response to checkpoint inhibi-
tors as a function of age.
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Edoxaban for Cancer-Associated Venous Thromboembolism
To the Editor: Regarding the article by Raskob 
et al. (Feb. 15 issue)1 comparing the safety and 
efficacy of edoxaban with subcutaneous dalte-
parin in patients with cancer-associated venous 
thromboembolism, we believe that these results 
may affect the quality of life of patients with can-
cer. The inconvenience of the use of long-term 
subcutaneous low-molecular-weight heparin ther-
apy might be avoided by the use of direct oral 
anticoagulant agents. The use of direct oral anti-
coagulants also reduces the cost of treatment for 
venous thromboembolism. However, low-molec-
ular-weight heparin remains the standard of care 
for management of acute venous thromboembo-
lism in patients with cancer. Guidelines current-
ly recommend at least 6 months of therapy with 
low-molecular-weight heparin up front and do 
not have a preference for direct oral anticoagu-
lants for patients who are not treated with low-
molecular-weight heparin.2
On the basis of the results of the current trial, 
some patients with cancer-associated venous 
thromboembolism should be switched to direct 
oral anticoagulants. Should we switch patients 
with rapidly progressive disease to direct oral 
anticoagulants, or should we consider this treat-
ment only for patients with responsive or stable 
disease? Do the results of the current trial apply 
to all direct oral anticoagulants? Navigating this 
switch implies many challenges for clinician 
oncologists.
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To the Editor: Regarding the article by Raskob 
et al. on edoxaban for cancer-associated venous 
thromboembolism, this trial showed the nonin-
feriority of edoxaban to dalteparin with respect 
to the composite outcome of recurrent venous 
thromboembolism or major bleeding (the pri-
mary end point). Treatment with edoxaban or 
dalteparin was to be continued for at least 6 to 
12 months in this trial. Although the treatment 
period defined by the protocol was longer than 
that in previous studies,1 events of recurrent ve-
nous thromboembolism were observed through-
out the treatment period. According to treatment 
guidelines for venous thromboembolism in pa-
tients with cancer,2 anticoagulant therapy with 
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low-molecular-weight heparin is recommended 
for at least 6 months. However, there is no con-
sensus about the maximum treatment period. 
Edoxaban is a novel oral agent and will be re-
garded as a new treatment option for cancer-
related thromboembolism, but a new question 
has now arisen: for how many months should we 
continue to give edoxaban?
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To the Editor: Raskob et al. report a higher rate 
of major gastrointestinal bleeding with edoxaban 
than with dalteparin among patients with cancer 
treated for venous thromboembolism. The in-
creased risk of gastrointestinal bleeding with di-
rect oral anticoagulants remains poorly under-
stood. Unlike antithrombin-dependent factor Xa 
inhibitors, direct factor Xa inhibitors inactivate 
both free and prothrombinase-bound factor Xa, 
further decreasing local thrombin generation and 
activation of platelets and endothelial cells through 
protease-activated receptors. Concordantly, edoxa-
ban suppresses tissue factor–induced platelet 
aggregation in vitro1 and was shown to fully in-
hibit arterial thrombosis in a rat model.2 In addi-
tion, direct factor Xa inhibitors modulate platelet 
glycoprotein VI shedding and the urinary excre-
tion of thromboxane B2, which indicate impaired 
platelet activation and thromboxane biosynthesis.3,4
In patients with cancer, edoxaban-mediated 
antiplatelet effects might contribute to gastroin-
testinal bleeding as a result of an impaired abil-
ity of platelets to form a plug at the endothelial 
surface, particularly at sites of highly vascular 
and friable tumor, which are known to bleed 
persistently. Thus, in patients with such gastro-
intestinal tumors, low-molecular-weight heparin 
remains a better option than direct oral antico-
agulants.
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To the Editor: Treatment of patients with can-
cer with heparin and low-molecular-weight hepa-
rin is associated with increased survival.1 The 
report by Raskob et al. shows a trend toward a 
higher survival rate among patients treated with 
low-molecular-weight heparin than among those 
treated with edoxaban. Heparin and low-molecular-
weight heparin have anticancer properties in 
animal models.2 We have shown that heparanase, 
an enzyme secreted from most cancer cells that 
degrades heparan sulfate in the extracellular ma-
trix, is inhibited by heparin and low-molecular-
weight heparin through competitive inhibition.3 
Heparin is a natural product extracted from bo-
vine lungs or pig intestine. Low-molecular-weight 
heparin is a semisynthetic molecule. We have 
shown that transgenic mice overexpressing hep-
aranase have lower baseline activated partial-
thromboplastin time values than control mice.3
Patients with cancer with high serum levels 
of heparanase have resistance to standard doses 
of low-molecular-weight heparin.4 Hypercoagu-
lation in patients with cancer seems to be re-
lated to molecules secreted from tumors such as 
heparanase, which degrades endogenous hepa-
rin.3,4 Treatment of patients with cancer with 
heparin and low-molecular-weight heparin is in-
dicated and should be coupled with close moni-
toring of anti–factor Xa activity and dose adjust-
ment to achieve therapeutic levels.4
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The authors reply: We agree with Calabrò and 
Curigliano that oral therapy with edoxaban is 
likely to improve the quality of life of patients 
with cancer-associated venous thromboembolism. 
We disagree, however, that low-molecular-weight 
heparin remains the standard of care for venous 
thromboembolism in patients with cancer. A pos-
sible direction derived from our results is that, 
after 5 days of low-molecular-weight heparin, 
edoxaban can replace low-molecular-weight hep-
arin for most patients with active cancer, includ-
ing those with advanced disease. The guidelines1 
were written and published before our results 
were available. Our results with edoxaban may 
not be translatable to other oral anticoagulants, 
since many anticancer therapies affect the cyto-
chrome P450 system, and the minimal metabo-
lism of edoxaban by this system distinguishes it 
from other oral factor Xa inhibitors.2
In response to Hironaka: evidence-based guide-
lines recommend extended anticoagulant therapy 
(no scheduled stop date) for a duration of more 
than 3 months in patients with venous thrombo-
embolism and cancer who do not have a high risk 
of bleeding.1 Oral edoxaban facilitates extended 
anticoagulant therapy and eliminates the need 
for months of subcutaneous injections of low-
molecular-weight heparin, providing an oppor-
tunity for enhanced patient adherence. Our results 
show the effectiveness and safety of edoxaban 
treatment for up to 1 year. We speculate that 
treatment should probably be continued until the 
cancer is resolved because these patients have a 
high risk of recurrent venous thromboembolism.
Frere and Dufilho raise interesting specula-
tions on the mechanism of gastrointestinal bleed-
ing that is associated with edoxaban in patients 
with gastrointestinal tumors. We disagree that 
low-molecular-weight heparin remains a better 
option for all patients with gastrointestinal tu-
mors. Some patients may choose the convenience 
of oral edoxaban despite an increased risk of 
gastrointestinal bleeding,3 especially since we 
found that the frequency of severe major bleed-
ing was similar with edoxaban and dalteparin. 
Stopping injections of low-molecular-weight 
heparin early (e.g., after 1 to 2 months), with the 
attendant increased risk of recurrent venous 
thromboembolism, could offset the lower risk of 
bleeding. These trade-offs should be discussed 
with patients and the patient’s preference con-
sidered.
The trial cited by Nasser is in the context of 
thromboembolism prevention during chemo-
therapy and is not relevant to the treatment of 
patients with established thromboembolism. The 
clinical trial data on a survival benefit of low-
molecular-weight heparin in patients with cancer 
without established thrombosis are conflicting.4 
We do not agree that monitoring of anti–factor 
Xa activity is indicated in patients with cancer 
treated with low-molecular-weight heparin ow-
ing to the lack of evidence that this improves the 
patient’s outcome. Edoxaban does not require 
anticoagulant monitoring and provides an effec-
tive, convenient alternative to low-molecular-
weight heparin for most patients with cancer-
associated venous thromboembolism.
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Primary Sjögren’s Syndrome
To the Editor: Mariette and Criswell (March 18 
issue)1 rightly point out that chronic pain and fa-
tigue are hallmarks of primary Sjögren’s syn-
drome, but they do not address the neurologic 
contributors to these symptoms. Although the 
central nervous system is indeed rarely affected 
in patients with primary Sjögren’s syndrome 
(<5% of patients), the prevalence of peripheral 
neuropathy ranges between 16 and 25%,2,3 which 
is higher than the 6% prevalence reported by 
Mariette and Criswell. Small-fiber polyneuropa-
thies account for at least 30% of these cases.2 
Large-fiber involvement causes ataxia, sensory loss, 
or motor deficit, whereas small-fiber involvement 
contributes to pain in particular, regardless of 
whether symptoms are length-dependent (distal 
polyneuropathy) or not (ganglionopathy). Small-
fiber denervation of the heart and microvessels 
may contribute to fatigue and exertional intoler-
ance, and small-fiber denervation of lachrymal 
and salivary glands may contribute to the sicca 
syndrome.
Given these prevalent neurologic symptoms 
and the absence of antibodies against Sjögren’s 
syndrome–related antigen A (anti-SSA) in 60% of 
the patients with primary Sjögren’s syndrome and 
small-fiber polyneuropathy,2 salivary-gland biop-
sy is an important consideration in patients with 
otherwise unexplained small-fiber polyneuropa-
thy. Questionnaires and laboratory tests for small-
fiber polyneuropathy, including skin biopsy and 
autonomic and neurophysiological tests,4 aid in the 
diagnosis. The results will influence decisions 
regarding treatments for symptoms (e.g., tricyclic 
antidepressants, gabapentin, pregabalin) and im-
munotherapies (e.g., immune globulin infusions).5 
Thus, neurologic considerations are integral to 
the diagnosis and treatment of primary Sjögren’s 
syndrome.
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To the Editor: Mariette and Criswell identify 
the systemic complications of primary Sjögren’s 
syndrome, but they do not mention the increased 
burden of cardiovascular disease, as has been de-
scribed in other systemic autoimmune diseases 
such as systemic lupus erythematosus and rheu-
matoid arthritis.1,2 Women with primary Sjögren’s 
syndrome are more likely to have myocardial in-
farction and cerebrovascular events than are 
healthy women of similar age.3 Hypertension and 
hypercholesterolemia were more prevalent among 
these patients with primary Sjögren’s syndrome, 
but other traditional risk factors such as smok-
ing, obesity, and diabetes mellitus were not.3 Un-
derlying systemic inflammation has been pro-
posed to contribute to this increased risk.
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